The Australian National University

Biotechnology Australia Pty, Ltd

Bioenterprises Pty Limited

American Home Products Corporation

Philip Ralph Lehrbach

Thomas Michael Barnes

Gregory John Russell-Jones

Toni Marie Antalis

Neil H Goss

Peter L Devine

Christopher Leigh Schwartzkoff

Thomas M Barnes

Jeffrey P Golder

Ross W Stephens

Michell A Clark

Richard Buchta

Michelle A Clark

The invention relates to vaccines which are suitable for the prevention of clostridial diseases of sheep (and lambs), providing an effective immunity for up to a year or more following a single injection or dose.

Veterinary vaccines

A class of carrier molecules which when covalently linked to an immunogen enhances the host's immune response to that immunogen, regardless of whether the complex of carrier and immunogen is administered parenterally, enterally, or orally to the host. Also provided are processes for production of the complexes, as well as hybrid DNA sequences encoding the complexes, recombinant DNA molecules bearing the hybrid DNA sequences, transformed hosts and vaccines comprising the complexes, and methods for production of the vaccine.

Immunopotentiation through covalent linkage between immunogen and

Class of carrier molecules which when covalently linked to an immunogen enhances the host's immune response to that immunogen regardless of whether the complex of carrier and immunogen is administered parenterally, enterally, or orally to the host. In addition, processes are provided for production of the complexes, as well as hybrid DNA sequences encoding complexes, recombinant DNA molecules bearing the hybrid DNA sequences, transformant hosts and vaccines comprising the complexes as well as methods for production of the vaccine.

Immunopotentiating complexes comprising TraT proteins

A novel human protein, minactivin, can be produced by recombinant DNA technology, Biologically active native minactivin, peptides derived from minactivin, and their amino acid sequences can also be purified.

Minactivin compositions and antibodies to minactivin

Minactivin (also known as Plasminogen Activator Inhibitor-2 [PAI-2]), a protein inactivator of urokinase-type plasminogen activator, has been shown to be a natural inactivator of this plasminogen activator which is associated with invasive tumors, and is therefore indicated as a crucial element in the body's normal defense against tumor invasion and metastasis. It may be produced by the cultivation of minactivin-producing cells in vitro, and recovery of the cell culture supernatant. By controlling the culture conditions, the protein minactivin may be produced in a partially purified form which may be used for diagnosis and treatment of tumors. The specification discloses purification of biologically active native minactivin, as well as peptides derived from minactivin and their amino acid sequences. The specification also discloses methods for production of PAI-2 by recombinant DNA technology, characterization of a PAI-2 gene sequence, and expression and purification of large quantities of biologically active PAI-2 from a recombinant host.

Human PAI-2

Growing community of inventors

Wahroonga, Australia

Philip Ralph Lehrbach